患者由来異種移植片モデルの市場規模、シェア、動向分析レポート：腫瘍タイプ別、モデルタイプ別、最終用途別、地域別、セグメント別予測、2025年～2030年

患者由来異種移植片モデル市場の成長と動向

患者由来異種移植片モデルの世界市場規模は、2030年には5億530万米ドルに達すると予測され、2025～2030年にかけてCAGR 9.64％で成長すると予測されます。

新たな治療オプションへの需要を促進するがんの負担増は、個別化治療への世界の大きな需要とともに、産業の成長を後押しします。患者由来異種移植（PDX）モデルは、過去10年間に認知度が高まってきました。このモデルは、患者由来の腫瘍組織を新鮮免疫不全マウスにイントロダクションするのが一般的です。これらのモデルは、前臨床検査において、薬剤の反応性や耐性に関する見込みのあるバイオマーカーを同定したり、治療反応における腫瘍の開発をモニターしたりするのに有効です。アバターモデル」と呼ばれる複数のモデルを一度に使用する共同臨床検査の概念は、最近人気が高まっており、PDXモデルを組み入れるまでに拡大しています。

さらに、PDXモデルは、生存期間の延長が確認された限られた数の患者に対する治療療法の決定を指示するために、いくつかの前向き検査で使用されました。COVID-19のパンデミックは産業に悪影響を与えました。臨床検査を中断させ、製薬・バイオ製薬企業の生産性も低下させました。Avantor Sciencesの調査によると、2020年7月時点で世界の臨床検査の70％が中断しています。COVID-19にもかかわらず、がん患者数の増加と製薬企業による研究開発活動の増加は、市場の成長に貢献すると考えられます。例えば、GLOBOCAN Report 2020によると、2020年には1,930万人のがん患者が新たに発生し、約1,000万人が死亡します。主要影響を受けるがんは、乳がん、肺がん、大腸がん、前立腺がんです。

患者由来異種移植片モデル市場レポートハイライト

• 世界的に乳がん症例が増加していることから、2024年の売上シェアは乳がんセグメントが31.7%を占めました。
• 例えば、女性の乳がんは230万人の新規症例が見込まれ、肺がんを抜いて最も罹患率の高い疾患となっています。
• 2024年にはマウスモデル部門が市場を独占しました。マウスは、免疫不全系統が確立されており、費用対効果が高く、取り扱いが容易であるため、異種移植研究に最もよく使用される動物タイプです。
• 製薬企業やバイオテクノロジー企業による研究開発活動のアウトソーシングが増加しているため、2024年にはCROとCDMOセグメントが市場を独占しました。
• 製薬・バイオ製薬企業は、創薬・開発を推進するためにより正確で信頼性の高い前臨床モデルへの需要が高まっていることから、2025～2030年にかけて大きな成長を遂げると予測されています。
• 北米の患者由来異種移植片モデル市場が世界市場を独占し、2024年には44.6％のシェアを占める。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 患者由来異種移植片モデル市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 市場分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 患者由来異種移植片モデル市場：腫瘍タイプ別、推定・動向分析

• セグメントダッシュボード
• 患者由来異種移植片モデルの世界市場：腫瘍タイプの変動分析
• 患者由来異種移植片モデルの世界の規模と動向分析、腫瘍タイプ別、2018～2030年
• 肺がん
• 膵臓がん
• 前立腺がん
• 乳がん
• その他

第5章 患者由来異種移植片モデル市場：モデルタイプ別、推定・動向分析

• セグメントダッシュボード
• 患者由来異種移植片モデルの世界市場：モデルタイプの変動分析
• 患者由来異種移植片モデルの世界の規模と動向分析、モデルタイプ別、2018～2030年
• マウスモデル
• ラットモデル

第6章 患者由来異種移植片モデル市場：最終用途別、推定・動向分析

• セグメントダッシュボード
• 患者由来異種移植片モデルの世界市場：最終用途の変動分析
• 患者由来異種移植片モデルの世界の規模と動向分析、最終用途別、2018～2030年
• 製薬・バイオ製薬企業
• 学術研究機関
• CROとCDMO

第7章 患者由来異種移植片モデル市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業分類
• 企業市況分析、2024年
• 企業プロファイル
  • Charles River Laboratories
  • The Jackson Laboratory
  • Crown Bioscience
  • Altogen Labs
  • Envigo
  • WuXi AppTec
  • Oncodesign
  • Hera Biolabs
  • XenTech
  • Abnova Corp.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 4 Global Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 5 Global Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 6 Global Patient-Derived Xenograft Model Market, by Region, 2018 - 2030 (USD Million)
• Table 7 North America Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
• Table 8 North America Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 9 North America Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 10 North America Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 11 U.S. Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 12 U.S. Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 14 Canada Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 15 Canada Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 16 Canada Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 17 Mexico Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 18 Mexico Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 19 Mexico Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 20 Europe Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
• Table 21 Europe Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 22 Europe Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 23 Europe Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 24 Germany Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 25 Germany Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 26 Germany Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 27 UK Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 28 UK Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 29 UK Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 30 France Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 31 France Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 32 France Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 33 Italy Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 34 Italy Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 35 Italy Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 36 Spain Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 37 Spain Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 38 Spain Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 39 Denmark Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 40 Denmark Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 41 Denmark Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 42 Sweden Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 43 Sweden Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 44 Sweden Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 45 Norway Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 46 Norway Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 47 Norway Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 52 China Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 53 China Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 54 China Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 55 Japan Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 56 Japan Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 57 Japan Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 58 India Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 59 India Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 60 India Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 61 South Korea Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 62 South Korea Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 63 South Korea Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 64 Australia Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 65 Australia Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 66 Australia Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 67 Thailand Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 68 Thailand Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 69 Thailand Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 70 Latin America Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
• Table 71 Latin America Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 72 Latin America Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 73 Latin America Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 74 Brazil Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 75 Brazil Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 76 Brazil Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 77 Argentina Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 78 Argentina Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 79 Argentina Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Patient-Derived Xenograft Model Market, by Country, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 84 South Africa Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 85 South Africa Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 86 South Africa Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 90 UAE Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 91 UAE Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 92 UAE Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)
• Table 93 Kuwait Patient-Derived Xenograft Model Market, by Tumor Type, 2018 - 2030 (USD Million)
• Table 94 Kuwait Patient-Derived Xenograft Model Market, by Model Type, 2018 - 2030 (USD Million)
• Table 95 Kuwait Patient-Derived Xenograft Model Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Forensic Genomics Market Segmentation
• Fig. 7 Market Snapshot, 2024
• Fig. 8 Market Trends & Outlook
• Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 12 Porter's Five Forces Analysis
• Fig. 13 Global Patient-Derived Xenograft Model Market: Tumor Type Key Takeaways
• Fig. 14 Global Patient-Derived Xenograft Model Market: Tumor Type Movement Analysis
• Fig. 15 Global Patient-Derived Xenograft Model Market, for Lung Cancer, 2018 - 2030 (USD Million)
• Fig. 16 Global Patient-Derived Xenograft Model Market, for Pancreatic Cancer, 2018 - 2030 (USD Million)
• Fig. 17 Global Patient-Derived Xenograft Model Market, for Prostate Cancer, 2018 - 2030 (USD Million)
• Fig. 18 Global Patient-Derived Xenograft Model Market, for Breast Cancer, 2018 - 2030 (USD Million)
• Fig. 19 Global Patient-Derived Xenograft Model Market, for Others, 2018 - 2030 (USD Million)
• Fig. 20 Global Patient-Derived Xenograft Model Market: Model Type Key Takeaways
• Fig. 21 Global Patient-Derived Xenograft Model Market: Model Type Movement Analysis
• Fig. 22 Global Patient-Derived Xenograft Model Market, for Mice Model, 2018 - 2030 (USD Million)
• Fig. 23 Global Patient-Derived Xenograft Model Market, for Rat Model, 2018 - 2030 (USD Million)
• Fig. 24 Global Patient-Derived Xenograft Model Market: End Use Key Takeaways
• Fig. 25 Global Patient-Derived Xenograft Model Market: End Use Movement Analysis
• Fig. 26 Global Patient-Derived Xenograft Model Market, for Pharmaceutical and Biopharmaceutical Companies, 2018 - 2030 (USD Million)
• Fig. 27 Global Patient-Derived Xenograft Model Market, for Academic and Research Institutes, 2018 - 2030 (USD Million)
• Fig. 28 Global Patient-Derived Xenograft Model Market, for A CRO's and CDMO's, 2018 - 2030 (USD Million)
• Fig. 29 Regional Marketplace: Key Takeaways
• Fig. 30 Regional Outlook, 2024 & 2030
• Fig. 31 North America Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 32 US Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 33 Canada Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 34 Mexico Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 35 Europe Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 36 Germany Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 37 UK Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 38 France Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 39 Italy Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 40 Spain Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 41 Denmark Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 42 Sweden Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 43 Norway Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 43 Asia Pacific Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 45 Japan Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 46 China Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 47 India Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 48 Australia Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 49 South Korea Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 50 Thailand Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 51 Latin America Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 52 Brazil Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 53 Argentina Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 54 Middle East and Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 55 South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 56 Saudi Arabia Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 57 UAE Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
• Fig. 58 Kuwait Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)

Patient-derived Xenograft Model Market Growth & Trends:

The global patient-derived xenograft model market size is expected to reach USD 505.3 million in 2030 and is projected to grow at a CAGR of 9.64% from 2025 to 2030. Growing burden of cancer, which is promoting the demand for new treatment options, along with significant demand for personalized therapies worldwide will boost the growth of the industry. Patient-derived Xenograft (PDX) models have garnered increasing awareness during the past decade. These types are typically characterized by the introduction of fresh immunodeficient mice with patient-derived tumor tissues. These models have been used with efficacy in preclinical studies to identify prospective biomarkers for drug response and resistance, as well as to monitor the development of tumors in therapy response. The concept of a co-clinical study, which involves using several models at once-referred to as "Avatar models"-has recently grown in popularity and has been expanded to incorporate PDX models.

Moreover, PDX models were used in a few prospective trials to direct therapeutic therapy decisions for a limited number of patients with confirmed extended survival. The COVID-19 pandemic had a negative impact on the industry. It disrupted the clinical trials and also reduced the productivity of pharmaceutical & biopharmaceutical companies. According to research by Avantor Sciences, 70% of global clinical trials were disrupted as of July 2020. 369 trials related to oncology had been delayed in the USA alone, central nervous system trials at 223, gastrointestinal trials at 116, and cardiovascular trials at 99. Despite COVID-19, the rising number of cancer cases & increased R&D activities by pharmaceutical companies will contribute to the growth of the market. For instance, as per the GLOBOCAN Report 2020, 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. The majorly impacted cancers were breast, lung, colorectal, and prostate cancer.

Patient-derived Xenograft Model Market Report Highlights:

• The breast cancer segment dominated with 31.7% of the revenue share in 2024 owing to increasing cases of breast cancer globally.
• For instance, female breast cancer is expected 2.3 million new cases & has surpassed lung cancer as the most prevalent disease diagnosed.
• The mice model segment dominated the market in 2024. Mice are the most commonly used species for xenograft studies due to their well-established immunodeficient strains, cost-effectiveness, and ease of handling.
• The CRO and CDMO segment dominated the market in 2024 owing to increasing outsourcing activities by pharmaceutical and biotechnology companies for research and development activities.
• Pharmaceutical and biopharmaceutical companies are projected to witness considerable growth from 2025 to 2030 owing to the increasing demand for more accurate and reliable preclinical models to advance drug discovery and development.
• North America patient-derived xenograft model market dominated the global market and accounted for a 44.6% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Tumor Type
  • 1.2.2. Model Type
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Patient-derived Xenograft Model Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Burden of Cancer Across the Globe
    • 3.2.1.2. Increasing R&D Investment for Cancer Research
    • 3.2.1.3. Demand for Personalized Therapies Worldwide
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Personalized PDX Models
    • 3.2.2.2. Stringent Regulations Towards the Use of Animal Models
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Patient-derived Xenograft Model Market: Tumor Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Patient-derived Xenograft Model Market; Tumor Type Movement Analysis
• 4.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by Tumor Type, 2018 to 2030 (USD Million)
• 4.4. Lung Cancer
  • 4.4.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Pancreatic Cancer
  • 4.5.1. Pancreatic cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Prostate Cancer
  • 4.6.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Breast Cancer
  • 4.7.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Patient-derived Xenograft Model Market: Model Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Patient-derived Xenograft Model Market; Model Type Movement Analysis
• 5.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by Model Type, 2018 to 2030 (USD Million)
• 5.4. Mice Model
  • 5.4.1. Mice model market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Rat Model
  • 5.5.1. Rat model market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Patient-derived Xenograft Model Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Patient-derived Xenograft Model Market; End Use Movement Analysis
• 6.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical and Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical and biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Academic and Research Institutes
  • 6.5.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. CRO's and CDMO's
  • 6.6.1. CRO's and CDMO's market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Patient-derived Xenograft Model Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Charles River Laboratories
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. The Jackson Laboratory
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Crown Bioscience
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Altogen Labs
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Envigo
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. WuXi AppTec
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Oncodesign
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Hera Biolabs
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. XenTech
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Abnova Corp.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives